Wilson's Disease Clinical Trials

29 clinical trials for Wilson's Disease across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• International Wilson's Disease Patient Registry (iWilson Registry) — RECRUITING
• Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease — RECRUITING · NA
• Cardiac Involvement in Wilson's Disease — RECRUITING · NA
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, SEAMLESS, ADAPTIVE,SAFETY, DOSE-FINDING, AND PHASE 3 CLINICAL STUDY OF UX701 AAV-MEDIATED GENE TRANSFER FOR THE TREATMENT OF WILSON DISEASE — RECRUITING · PHASE3
• A Registered Cohort Study on Wilson's Disease — RECRUITING
• Subclinical Myocardial Dysfunction in Children With Wilson's Disease — ACTIVE_NOT_RECRUITING
• A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) — NOT_YET_RECRUITING · PHASE1
• Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. — NOT_YET_RECRUITING · PHASE3
• Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease — NOT_YET_RECRUITING · PHASE1
• Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride — COMPLETED · PHASE2
• Exchangeable and Relative Exchangeable Copper as an Alternative to 24-Hour Urinary Copper in Wilson's Disease Monitoring — COMPLETED
• COMPARISON OF ZINC ACETATE DOSE REGIMENS (GALZIN VS. ET-700) FOR THE TREATMENT OF WILSON DISEASE: A PHARMACODYNAMIC 64CUCL2 PET/CT STUDY IN HEALTHY PARTICIPANTS — TERMINATED · PHASE2
• A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease — ACTIVE_NOT_RECRUITING · PHASE1
• Multifaceted Assessment of Patients With Wilson's Disease in a Low-Resource Setting in Upper Egypt: Service Integration, Psychosocial Burden, Dietary Practices, and the Geo-Spatial Disease Map — NOT_YET_RECRUITING
• Endocrine Dysfunction in Pediatric Wilson's Disease — NOT_YET_RECRUITING
• WILSTIM - DBS (WILson STIMulation - Deep Brain Stimulation) — COMPLETED · NA
• Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). — COMPLETED · PHASE1
• ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders — ACTIVE_NOT_RECRUITING · NA
• Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan. — COMPLETED · PHASE3
• Open label, Multicenter, Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) and to Investigate the Efficacy and Safety in Wilson’s Disease Patients — OTHER · PHASE4
• A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson's Disease — OTHER · PHASE2
• Gandouling in the Treatment of Wilson's Disease — OTHER · PHASE4
• Early Detection of Cardiac Affection in Patients of Wilson's Disease — NOT_YET_RECRUITING
• A PHASE 2, SINGLE-ARM, PATHOLOGIST-BLINDED STUDY USING LIVER BIOPSY SPECIMENS TO ASSESS COPPER CONCENTRATION AND HISTOPATHOLOGIC CHANGES IN PATIENTS WITH WILSON DISEASE WHO ARE TREATED WITH ALXN1840 FOR 48 WEEKS FOLLOWED BY AN EXTENSION TREATMENT PERIOD WITH ALXN1840 FOR UP TO AN ADDITIONAL 48 WEEKS. — COMPLETED · PHASE2
• Cohort Research on Wilson's Disease — OTHER
• A PHASE 3, RANDOMIZED, RATER-BLINDED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1840 ADMINISTERED FOR 48 WEEKS VERSUS STANDARD OF CARE IN PATIENTS WITH WILSON DISEASE AGED 12 YEARS AND OLDER WITH AN EXTENSION PERIOD OF UP TO 60 MONTHS — COMPLETED · PHASE3
• The Individual Therapy for Patients With Wilson's Disease — OTHER · PHASE1
• Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis — COMPLETED · NA
• A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients — COMPLETED · PHASE1

Refine this search